Moleculin Biotech, Inc., (NASDAQ: MBRX) Starts Presentation at LD Micro Main Event

Moleculin Biotech (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin also has two … Continue reading “Moleculin Biotech, Inc., (NASDAQ: MBRX) Starts Presentation at LD Micro Main Event”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Files Annamycin IND with FDA for Acute Myeloid Leukemia

Shares of Moleculin Biotech (NASDAQ: MBRX) are trading 7% higher this morning following the company’s news that it has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to study Annamycin in the treatment of relapsed or refractory acute myeloid leukemia (AML). The company expects the FDA will allow the IND to … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Files Annamycin IND with FDA for Acute Myeloid Leukemia”

NetworkNewsBreaks – Moleculin Biotech, Inc.’s (NASDAQ: MBRX) CEO Shares Opinion on Recent FDA Drug Approvals for Acute Myeloid Leukemia

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 9% mid-day following the company’s comments regarding the recent FDA approvals for new drugs for the treatment of acute myeloid leukemia (AML). The company’s drug candidate, Annamycin, is currently being evaluated for the treatment of relapsed or refractory AML. “While these new drugs make valuable incremental improvements … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc.’s (NASDAQ: MBRX) CEO Shares Opinion on Recent FDA Drug Approvals for Acute Myeloid Leukemia”

Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment

NASDAQ Biotechnology Index up and climbing Developing new treatment for acute myeloid leukemia (AML) Lead candidate, Annamycin, now at phase II Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date … Continue reading “Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO

Shares of Moleculin Biotech (NASDAQ: MBRX) rose 7% this morning on news that the company has selected Bioscience SA, a Polish contract research organization (CRO), to begin identifying and preparing clinical testing sites in Poland for Annamycin. The company’s drug candidate, Annamycin, is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO”

Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch”

Oncology pipeline features significant safety/efficacy advantages Lead candidate poised for FDA acceleration due to significant unmet need in AML Broad-spectrum applicability of WP1066 & WP1122 portfolios of molecules For preclinical oncology biopharma Moleculin Biotech, Inc. (NASDAQ: MBRX), the quest to deliver potentially revolutionary anti-cancer drugs to the market is enkindled by a close association with … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch””

Moleculin Biotech, Inc. (NASDAQ: MBRX)

Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, is engaged in the development of next-generation anti-cancer drug candidates. Notably, the world’s largest cancer research facility, M.D. Anderson Cancer Center, was a key part of the discovery process that resulted in some of the candidates in the company’s development pipeline and it continues to collaborate … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX)”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 11% after the company named Dr. Lidia Gil of Poznan University of Medical Sciences in Poznan, Poland, as the lead European Principal Investigator for the upcoming planned phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The trial will … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Discovery of Metabolic Inhibitor with Potential to Treat Pancreatic Cancer; Shares Rise

Shares of Moleculin Biotech (NASDAQ: MBRX) are up more than 30% after the company said that WP1234, a metabolic inhibitor, is a positive drug candidate to be studied for the potential to treat pancreatic cancer. Pancreatic cancer is still considered mostly untreatable, so any improvement in treating this disease could symbolize a significant clinical benefit. … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Discovery of Metabolic Inhibitor with Potential to Treat Pancreatic Cancer; Shares Rise”

Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at LD Micro 2017 Invitational

Moleculin Biotech (NASDAQ: MBRX) is a preclinical-stage pharmaceutical company that focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at LD Micro 2017 Invitational”

Contact us: 212.418.1217